Latest Atsena Therapeutics News
Oct 2, 2023
DURHAM – Atsena Therapeutics – a clinical-stage gene therapy company that’s fighting to reverse and prevent blindness and recently launched a clinical trial for a possible treatment , has landed $24.5 million from investors to carry on the battle. Atsena wants to raise $30 million. The company raised some $25 million in 2020. Atsena recently announced that the first patient has been enrolled in a Phase I-II clinical trial for a treatment of a “subretinal injection” that it says can “achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.” The treatment is for X-linked retinoschisis, or XLRS. It is a “condition characterized by impaired vision that begins in childhood and occurs almost exclusively in males,” according to MedlinePlus.gov . More Atsena coverage
Atsena Therapeutics Frequently Asked Questions (FAQ)
When was Atsena Therapeutics founded?
Atsena Therapeutics was founded in 2019.
Where is Atsena Therapeutics's headquarters?
Atsena Therapeutics's headquarters is located at 280 S. Magnum Street, Durham.
What is Atsena Therapeutics's latest funding round?
Atsena Therapeutics's latest funding round is Series A.
How much did Atsena Therapeutics raise?
Atsena Therapeutics raised a total of $55M.
Who are the investors of Atsena Therapeutics?
Investors of Atsena Therapeutics include The Manning Family Foundation, Osage University Partners, Hatteras Venture, Abingworth, Sofinnova Ventures and 5 more.